Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology

• Main Authors: Iméne Ben Toumia (Author), Tiziana Bachetti (Author), Leila Chekir-Ghedira (Author), Aldo Profumo (Author), Marco Ponassi (Author), Alessandro Di Domizio (Author), Alberto Izzotti (Author), Salvatore Sciacca (Author), Caterina Puglisi (Author), Stefano Forte (Author), Raffaella Giuffrida (Author), Cristina Colarossi (Author), Danilo Milardi (Author), Giuseppe Grasso (Author), Valeria Lanza (Author), Stefano Fiordoro (Author), Giacomo Drago (Author), Kateryna Tkachenko (Author), Barbara Cardinali (Author), Paolo Romano (Author), Erika Iervasi (Author), Gabriela Coronel Vargas (Author), Paola Barboro (Author), Franz Heinrich Kohnke (Author), Camillo Rosano (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and purpose: Lung cancer is the leading cause of death in both men and women, constituting a major public health problem worldwide. Non-small-cell lung cancer accounts for 85%-90% of all lung cancers. We propose a compound that successfully fights tumor growth in vivo by targeting the enz...